PolyMedix Announces Three Presentations at Upcoming American Society of Hematology Meeting

RADNOR, Pa.--(BUSINESS WIRE)--Nov 22, 2010 - PolyMedix, Inc. (OTCBB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced that three abstracts were accepted for two oral presentations and one poster presentation at the 52nd American Society of Hematology Annual Meeting and Exposition. The meeting will take place at the Orange County Convention Center in Orlando, Florida from December 4-7.

Data from PolyMedix's Phase 1B/2 dose-ranging clinical trial with PMX-60056 and data on next generation heptagonist compounds will be presented:

Reversal of Heparin by Novel Synthetic Antagonist PMX-60056 Exhibits a Linear Dose-Response Relationship

 

Poster Presentation Date/Time: Monday, December 6, 2010 at 6:00 – 8:00 PM

 

Presenter: Eric McAllister

 

Abstract Control Number: 3329

 

Location: Hall A3/A4 Poster Board III-108

 

 
Optimized Fully-Synthetic Salicylamide Heparin Antagonists Have Greater Efficacy versus LMWHS and Display Improved Hemodynamic Responses as Compared to Protamine

 

Oral Presentation Date/Time: Monday, December 6, 2010 at 8:00AM

 

Presenter: Richard W. Scott, Ph.D.

 

Abstract Control Number: 191

 

Location: 230

 

 
Arylamides: Discovery of a Novel Class of Fully-Synthetic Small Molecule Heparin and LMWH Antagonists
Oral Presentation Date/Time: Tuesday, December 7, 2010 at 1:00 PM

 

Poster Session Date/Time: Tuesday, December 7, 2010 at 12:00 – 1:30 PM

 

Presenter: Richard W. Scott, Ph.D.

 

Abstract Control Number: 1096

 

Location: 414 AB Poster Board I-76

 

 
About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug candidates. PolyMedix's lead antibiotic compound, PMX-30063, is currently in Phase 2 clinical trials. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including methicillin resistant Staphylococcus aureus (MRSA). PolyMedix's lead heptagonist compound, PMX-60056, has completed Phase 1 testing and is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides™. PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit our website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedix's need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

 

Contact: PolyMedix, Inc.
Lisa Caperelli, 484-598-2406
Director, Investor Relations & Corporate Communications
lcaperelli@polymedix.com

 

 

Posted: November 2010

View comments

Hide
(web3)